In this week’s video, Dr. Brian G.M. Durie explains that the underlying biology of light chain myeloma is very similar to IgG or IgA myeloma.

If you have light chain myeloma, you are not at a higher risk for poorer outcomes than those patients with other types of myeloma.

Have a question? Submit it to

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at

Previous Post
Can you explain the results of the IFM 2009 trial?
Next Post
As Federally Funded Medical Research Decreases in the US, Chinese Biotech Surges 500 Percent

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.